June 5, 2022

Immunotherapy, Blog, Cancer

Gregory Beatty

The neutrophil to lymphocyte ratio is a prognostic biomarker of CD40 immunotherapy.

Gregory Beatty

June 9, 2022

Historical controls for trials in pancreatic cancer

Gregory Beatty

June 9, 2022

What are the right historical controls for Phase II studies in 1L metastatic pancreatic cancer?

Gregory Beatty

June 5, 2022

Immunotherapy, Blog, Cancer

Biomarkers for CD40 immunotherapy

Gregory Beatty

June 5, 2022

Immunotherapy, Blog, Cancer

The neutrophil to lymphocyte ratio is a prognostic biomarker of CD40 immunotherapy.

Gregory Beatty

April 30, 2022

Gregory Beatty

April 30, 2022

Beatty Lab starts new blog to share and inspire in the field of cancer immunotherapy.

The Beatty Laboratory is part of the Perelman School of Medicine at the University of Pennsylvania.